Citations

Clear

4847 citation(s) found for "Tu, Eric".

Core outcomes in nerve surgery: development of a core outcome set for common peroneal (fibular) neuropathy
Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Desai, Ketan, Garozzo, Debora, Guedes, Fernando , Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.3171/2024.5.jns24614 | PMID 39151186 Get It

OBJECTIVE Common peroneal (fibular) neuropathy is the most common mononeuropathy of the lower extremity. Despite this, there are surprisingly few studies on the topic, and a knowledge gap remains in the literature. As one attempts to address this knowledge gap, a core outcome set (COS) is needed to guide the planning phases of future studies to allow synthesis and comparability of these studies. The objective of this study was to develop the COS–common peroneal neuropathy (CoPe) using a modified Delphi approach. METHODS A 5-stage approach was used to develop the COS-CoPe: 1) stage 1, consortium development; 2) stage 2, a literature review to identify potential outcome measures; 3) stage 3, a Delphi survey to develop consensus on outcomes for inclusion; 4) stage 4, a Delphi survey to develop definitions; and 5) stage 5, a consensus meeting to finalize COS and definitions. The study followed the COS–STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 23 participants, all neurological surgeons, representing 13 countries. The final COS-CoPe consisted of 31 data points/outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months. The consensus optimal time points for assessment were preoperatively and 3, 6, 12, and 24 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS and provided definitions, methods of implementation, and time points for assessment. The COS-CoPe should serve as a minimum set of data that should be collected in all future neurosurgical studies on common peroneal neuropathy. Incorporation of this COS should help improve consistency in reporting, data synthesis, and comparability, and should minimize outcome reporting bias.
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Benson, Al B. , Adam, Mohamed A. , Chang, George J. , Chen, Yi-Jen, Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Haste, Paul, Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Malla, Midhun , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Parikh, Aparna, Patel, Hitendra , Shibata, David , Shogan, Benjamin D. , Skibber, John M., Sofocleous, Constantinos T. , Tavakkoli, Anna , Willett, Christopher G. , Wu, Christina, Jones, Frankie, Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Chen, Yi‐Jen , Ciombor, Kristen K. , Cohen, Stacey A. , Hussan, Hisham , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 366-375

10.6004/jnccn.2024.0041 | PMID 39151454 Get It

The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Poster 304: Isolating The Medial Meniscal Artery with Ultrasonography: Anatomical Characterization of the Novel Vascular Structure and a Technical Note on Imaging Technique
Azua, Eric N. , Khan, Zeeshan A. , Hevesi, Mario, Pascual, Tomás , Hevesi, Mario , Chahla, Jorge

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00271 Get It

Objectives: The vascularity of the human meniscus was first famously described by Arnoczky and Warren, who used histological analysis to map out vessel contributions to the medial and lateral menisci. This study determined that the medial and lateral superior and inferior genicular arteries branches give rise to a perimeniscal capillary plexus within the capsular and synovial tissues of the knee. However, since this study, there have been limited investigations into the macro- and microvascularity of the menisci. This includes anatomical, biomechanical, and imaging studies. Doppler ultrasound is an easily accessible, safe, and non-invasive modality that gives clinicians real-time visualization of vascular anatomy. To date, there have been no ultrasound studies that have highlighted vascular deviations from the popliteal artery to the medical meniscus, including the newly discovered medial meniscal artery (MMA), as described in Part 1 of this study (Figure 1, from Part 1 of this investigation). The purpose of this study was to use find a reproducible ultrasound technique to identify the MMA and provide a detailed characterization of the vessel’s precise anatomy. We hypothesized that the MMA would be consistently identifiable in vivo using ultrasound imaging and that multiple anatomic variants of the MMA would exist. Methods: Fifty-six patients underwent ultrasound examination of the left knee. Patient demographics were collected. The MMA was isolated by one of two techniques. In the first approach, the inferior medial genicular artery (IMGA) was isolated and followed back to the popliteal artery, where the examiner then coursed the artery proximally to find medial-sided vasculature branching to the medial meniscus. In the second approach, the probe was started on the medial meniscus and once an arterial supply was found, it was traced back to the popliteal artery. Once the MMA was isolated by either technique, the following variables were measured: presence or absence of MMA, artery diameter, presence of arterial calcifications or atheromatous plaques, and any vascular variations. Once the MMA was found and isolated in the left knee, its presence was investigated in the right knee. Results: The MMA was identified in 50/56 patients (89.2%). The average vessel diameter was 0.89 mm (SD ± 0.39). All 50 patients with a MMA present on the left knee also had the presence of the artery on the right knee. None of the MMA isolated in this study were noted to have any plaques or calcifications. 45 patients were noted to have a Type 1 MMA, whereas five patients were noted to have a Type 2 MMA where the vessel shares an origin with the IMGA (Figure 2). Conclusions: This is the first study to utilize ultrasound to isolate and characterize the MMA in a in vivo human model. The MMA can be consistently seen on ultrasonography in the majority of patients and ultrasound examination demonstrated that the artery perforates into the meniscal tissue to contribute to the meniscal microplexus. The key methods to ensure reproducible identification of the artery and patient characteristics that produce lesser quality images are discussed in detail. Ultrasound identification in clinic may serve as a point-of-care diagnostic modality to determine the likelihood of success of procedures such as medial meniscal repair, given the artery provides a direct blood supply to the meniscus. The MMA may play a pivotal role in meniscal injury, repair, healing, and preservation. Future studies are necessary to determine the extent to which this vessel contributes to said mechanisms.
Methotrexate and Rituximab Use in Highly Recurrent Idiopathic Subglottic Stenosis
Awadallah, Andrew S. , Bowen, Andrew J. , Ali, Hawa M. , O’Byrne, Thomas J., Padilla, Hannah, Khalil, Yousuf H. , Aden, Aisha A. , Edell, Eric S. , Bayan, Semirra L. , Ekbom, Dale C. , Padilla, Hannah M , Bowen, Andrew Jay , Awadallah, Andrew , Bayan, Semirra , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | August 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.31686 | PMID 39140225 Get It

ObjectiveTo evaluate the impact of methotrexate and rituximab therapy on highly recurrent idiopathic subglottic stenosis (iSGS) patients with a negative antineutrophil cytoplasmic antibody titer cANCA(−).MethodsThis was a retrospective cohort study of highly recurrent iSGS patients who recurred within 1 year or less and were treated with methotrexate (MTX), and rituximab (RTX), or a combination of both at different time points (MTX/RTX). Average surgical durations before and after drug treatment were summarized, and the differences were calculated.ResultsA total of 21 female patients with median age of 62 years were included. Fifteen patients were treated with MTX, three were treated with RTX, and five treated with both. Patients treated with immunosuppressants showed a trend toward longer intervals between operations (mean pre‐drug interval: 338; mean post‐drug interval: 697 days) (p‐value = 0.25). Three patients did not recur following drug initiation with median follow‐up of 1265 days. All three treatment groups demonstrated a trend toward increased post‐drug recurrence intervals (MTX: 444 days, RTX: 374 days, MTX/RTX: 55 days), that was not statistically significant. Patients with prior dilations demonstrated longer post‐drug recurrence intervals (mean pre‐drug interval: 341 days, mean post‐drug interval 978 days) (p‐value = 0.17). Four patients in the cohort with the highest recurring disease improved from mean 129 days between operations to 509 days with drug therapy. The most common drug side effect was nausea (16%).ConclusionMTX and RTX may be treatment options for some highly recurrent iSGS patients. Initial results are variable and demonstrate a need for further research on drug candidacy.Level of Evidence3 Laryngoscope, 2024
Artificial intelligence‐assisted ultrasound‐guided regional anaesthesia: An explorative scoping review
Marino, Martina , Hagh, Rebecca, Senorski, Eric Hamrin , Longo, Umile Giuseppe , Oeding, Jacob F. , Szell, Anita , Samuelsson, Kristian , Hamrin Senorski, Eric , Samuelsson, Kristian , Oeding, Jacob F , Longo, Umile Giuseppe , Nellgård, Bengt

Mayo Clinic

Journal of Experimental Orthopaedics | August 14, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/jeo2.12104 | PMID 39144578 Get It

AbstractPurposeThe present study reviews the available scientific literature on artificial intelligence (AI)‐assisted ultrasound‐guided regional anaesthesia (UGRA) and evaluates the reported intraprocedural parameters and postprocedural outcomes.MethodsA literature search was performed on 19 September 2023, using the Medline, EMBASE, CINAHL, Cochrane Library and Google Scholar databases by experts in electronic searching. All study designs were considered with no restrictions regarding patient characteristics or cohort size. Outcomes assessed included the accuracy of AI‐model tracking, success at the first attempt, differences in outcomes between AI‐assisted and unassisted UGRA, operator feedback and case‐report data.ResultsA joint adaptive median binary pattern (JAMBP) has been applied to improve the tracking procedure, while a particle filter (PF) is involved in feature extraction. JAMBP combined with PF was most accurate on all images for landmark identification, with accuracy scores of 0.83, 0.93 and 0.93 on original, preprocessed and filtered images, respectively. Evaluation of first‐attempt success of spinal needle insertion revealed first‐attempt success in most patients. When comparing AI application versus UGRA alone, a significant statistical difference (p < 0.05) was found for correct block view, correct structure identification and decrease in mean injection time, needle track adjustments and bone encounters in favour of having AI assistance. Assessment of operator feedback revealed that expert and nonexpert operator feedback was overall positive.ConclusionAI appears promising to enhance UGRA as well as to positively influence operator training. AI application of UGRA may improve the identification of anatomical structures and provide guidance for needle placement, reducing the risk of complications and improving patient outcomes.Level of EvidenceLevel IV.
Steering the multidisciplinary landscape of vascular medicine: Collaboration as the key to success for aspiring vascular medicine specialists
Cohoon, Kevin P. , Porres‐Aguilar, Mateo , Tomihama, Roger T. , Thomas, Sneha , Rogers, Everett M., Brunton, Nichole , Henkin, Stanislav , Hornacek, Deborah , Secemsky, Eric A. , Buckley, Anthony , Brunton, Nichole E , Henkin, Stanislav , Secemsky, Eric A , Porres-Aguilar, Mateo , Tomihama, Roger

Mayo Clinic

Vascular Medicine | August 13, 2024 | Volume: 29 | Issue: 4 | Pages: 462-466

10.1177/1358863x241262723 | PMID 39135266 Get It

Comparison of Outcomes After Cochlear Implantation in a Veteran Versus Nonveteran Population
Tripathi, Siddhant H. , Adams, Sarah M. , Petito, Gabrielle T. , Grisel, Jedidiah J. , Breen, Joseph T. , Patil, Reena Dhanda , Breen, Joseph, Wong, Eric M., Shapiro, Scott

Mayo Clinic

Otology & Neurotology Open | August 12, 2024 | Volume: 4 | Issue: 3 | Pages: e058

10.1097/ono.0000000000000058 | PMID 39328868 Get It

Objective: To evaluate for equivalence in postoperative changes of speech recognition scores in a veteran patient population undergoing cochlear implantation (CI) compared to matched nonveteran patients. Study Design: Retrospective chart review. Setting: Tertiary referral center. Patients: A total of 83 veteran patients who underwent CI at a single Veterans Affairs Medical Center (VA cohort) were matched to 83 nonveteran patients from the Health Insurance Portability and Accountability Act-secure, Encrypted, Research, Management and Evaluation Solution database (HERMES cohort) based on age, sex, and baseline Consonant–Nucleus–Consonant (CNC) scores. Intervention: Patients underwent CI. Main Outcome Measures: Comparison of postoperative CNC and Arizona Biomedical Institute recognition scores. Results: The mean difference and lower confidence interval of CNC scores between matched Veterans Affairs and HERMES cohorts were within a −ΔNI boundary of −15% at the 3-month (mean = 6.15, lower confidence interval = −2.38), 6-month (mean = 7.36, lower confidence interval = −2.21), and 12-month (mean = 4.03, lower confidence interval = −4.88) postoperative time points. The mean difference and lower confidence interval of Arizona Biomedical Institute scores between cohorts were within the −ΔNI boundary of −30% at 3 months (mean = 1, lower confidence interval = −8.71), 6 months (mean = 0.31, lower confidence interval = −12.30), and 12 months (mean = 0.72, lower confidence interval = −10.48). Conclusion: Our veteran population demonstrated improvements in speech recognition scores after CI comparable to a matched nonveteran population. Although veterans face unique factors that affect their hearing, access to medical care, and baseline general health, these findings affirm appropriate veteran candidates should be offered CI.
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
Puledda, Francesca , Diener, Hans‐Christoph , Al‐Khazali, Haidar M. , Ashina, Sait , Liebler, Eric , Chu, Min Kyung , Cocores, Alexandra, Dodd-Glover, Freda , Ekizoğlu, Esme , Göbel, Carl, Hassan, Amr , Hirata, Koichi , Hoffmann, Jan , Jenkins, Bronwyn , Kamm, Katharina , Martinelli, Daniele , Monteith, Teshamae , Romanenko, V.I. , Vandenbussche, Nicolas , Tassorelli, Cristina , Diener, Hans-Christoph , Ashina, Sait , Chu, Min Kyung , Garcia-Azorin, David , Hoffmann, Jan , Kamm, Katharina , Lee, Mi Ji , Ling, Yu-Hsiang , Martinelli, Daniele , Monteith, Teshamae S , Ornello, Raffaele , Rozen, Todd D. , Pozo-Rosich, Patricia , Souza, Marcio Nattan P , Thuraiaiyah, Janu , Togha, Mansoureh , Wang, Shuu-Jiun , Yu, Shengyuan , Tassorelli, Cristina , Al-Khazali, Haidar M , Puledda, Francesca , Hassan, Amr , Sacco, Simona , Ashina, Messoud , Burstein, Rami , Cipriani, Andrea , Göbel, Carl Hartmut , Goicochea, María Teresa , Lee, Mi Ji , Lisicki, Marco , Ornello, Raffaele , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Schwedt, Todd J. , Takizawa, Tsubasa , Terwindt, Gisela M. , Wang, Shuu‐Jiun

Mayo Clinic

Cephalalgia | August 12, 2024 | Volume: 44 | Issue: 8 | Pages: No page available

10.1177/03331024241252666 | PMID 39133176 Get It

Background In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications. Methods An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group. Results A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained. Conclusion Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia
Sosero, Yuri L. , Bandrés‐Ciga, Sara , Tocino, Maria Teresa Periñan, Belloso, Dìaz R., Gómez‐Garre, Pilar , Faouzi, Johann , Pavelka, Lukas , Marques, Tainá M. , May, Patrick , Milanowski, Łukasz , Uitti, Ryan J. , Hilten, Jacobus J. van , Simon, David K. , Eberly, Shirley , Krohn, Lynne , Freeman, Kathryn , Ruskey, Jennifer A. , Asayesh, Farnaz , Menéndez‐González, Manuel , Pástor, Pau , Ross, Owen A. , Krüger, Rejko , Kõks, Sulev, Mir, Pablo , Klucken, Jochen , Gómez‐Garre, Pilar , Fatima, Noor , Gómez-Garre, Pilar , May, Patrick , Milanowski, Łukasz M , Wszolek, Z.K. , Simon, David K , Ross, Owen A , Corvol, Jean-Christophe , Koks, Sulev , Mir, Pablo , de Bie, Rob M A , Iwaki, Hirotaka , Gan-Or, Ziv , Pastor, Pau , Ferwerda, Bart , Taba, Pille , Gomes, Clarissa P. C. , Kolodkin, Alexey N. , Wszołek, Zbigniew K. , Heutink, Peter , Álvarez, Ignacio , Yu, Eric , Freeman, Kathryn, Rudakou, Uladzislau , Corvol, Jean‐Christophe , Bie, Rob M.A. de , Gan‐Or, Ziv

Mayo Clinic

Movement Disorders | August 12, 2024 | Volume: 39 | Issue: 10 | Pages: 1773-1783

10.1002/mds.29960 | PMID 39132902 Get It

Abstract Background Levodopa‐induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2 . Objectives Our goal was to investigate the effects of genetic variants on risk and time to LID. Methods We performed a genome‐wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID. Results We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95% confidence interval [CI], 1.21–2.26; P = 0.0017) and LRRK2 variants with reduced time to LID onset (hazard ratio [HR] = 1.42; 95% CI, 1.09–1.84; P = 0.0098). The fourth quartile of the PD PRS was associated with increased LID risk (OR fourth_quartile = 1.27; 95% CI, 1.03–1.56; P = 0.0210). The third and fourth dopamine pathway PRS quartiles were associated with a reduced time to development of LID (HR third_quartile = 1.38; 95% CI, 1.07–1.79; P = 0.0128; HR fourth_quartile = 1.38; 95% CI = 1.06–1.78; P = 0.0147). Conclusions This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Konda, Bhavana , Sherman, Eric J. , Morris, John C, Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 9, 2024 | Volume: 110 | Issue: 3 | Pages: 830-837

10.1210/clinem/dgae512 | PMID 39133806 Get It

Abstract Background This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. Methods Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. Results Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. Conclusion CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300